Analysis of more than 400,000 women provides case-control evidence for BRCA1 and BRCA2 variant classification
Preprint
Abstract
Clinical genetic testing identifies variants causal for hereditary cancer, information that is used for risk assessment and clinical management. Unfortunately, some variants identified are of uncertain clinical significance (VUS), complicating patient management. Case-control data is one evidence type used to classify VUS, and previous findings indicate that case-control likelihood ratios (LRs) outperform odds ratios for variant classification. As an initiative of the Evidence-based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) Analytical Working Group we analyzed germline sequencing data of BRCA1 and BRCA2 from 96,691 female breast cancer cases and 303,925 unaffected controls from three studies: the BRIDGES study of the Breast Cancer Association Consortium, the Cancer Risk Estimates Related to Susceptibility consortium, and the UK Biobank. We observed 11,227 BRCA1 and BRCA2 variants, with 6,921 being coding, covering 23.4% of BRCA1 and BRCA2 VUS in ClinVar and 19.2% of ClinVar curated (likely) benign or pathogenic variants. Case-control LR evidence was highly consistent with ClinVar assertions for (likely) benign or pathogenic variants; exhibiting 99.1% sensitivity and 95.4% specificity for BRCA1 and 92.2% sensitivity and 86.6% specificity for BRCA2 . This approach provides case-control evidence for 785 unclassified variants, that can serve as a valuable element for clinical classification.Keywords
All Related Versions
- Published version: Nature Communications, 16 (1), 1.
This publication has 29 references indexed in Scilit:
- Functional analysis and clinical classification of 462 germline BRCA2 missense variants affecting the DNA binding domainThe American Journal of Human Genetics, 2024
- Calibration of computational tools for missense variant pathogenicity classification and ClinGen recommendations for PP3/BP4 criteriaThe American Journal of Human Genetics, 2022
- Fitting a naturally scaled point system to the ACMG/AMP variant classification guidelinesHuman Mutation, 2020
- Large scale multifactorial likelihood quantitative analysis of BRCA1 and BRCA2 variants: An ENIGMA resource to support clinical variant classificationHuman Mutation, 2019
- Modeling the ACMG/AMP variant classification guidelines as a Bayesian classification frameworkGenetics in Medicine, 2018
- PERCH: A Unified Framework for Disease Gene PrioritizationHuman Mutation, 2016
- REVEL: An Ensemble Method for Predicting the Pathogenicity of Rare Missense VariantsThe American Journal of Human Genetics, 2016
- Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular PathologyGenetics in Medicine, 2015
- ENIGMA-Evidence-based network for the interpretation of germline mutant alleles: An international initiative to evaluate risk and clinical significance associated with sequence variation in BRCA1 and BRCA2 genesHuman Mutation, 2011
- Categorical Data Analysis2002